According to contract development and manufacturing organization (CDMO), the investment follows an increasing customer demand for analytical development and validation services to support cGMP products at the clinical stage.
“Demand for analytical and process development and manufacturing at early clinical stages is growing as we see the record number of projects in the clinical pipeline," Brian Swierenga, site director, VP operations, Cambrex High Point told Outsourcing-Pharma.com.
"At the same time the complexity of the molecules and the more stringent regulatory requirements has led to a greater proportional growth in demand for analytical resources," he added.
Cambrex purchased the 35,000 square foot High Point site from PharmaCore in October 2016, since which time it has invested more than $5m in the site. The most recent investment follows the addition of a fourth reactor suite at the facility in May of this year.
Equipment installation at the High Point facility will begin in Q3 2017. Validation and start up is expected in Q4 2017.
As part of the expansion, the company also plans to add twelve new analytical development scientists to its research and development team.
Last month, Cambrex also announced a $24m investment to open a new facility to manufacture high potent APIs at its Charles City, Iowa plant.